[2,2-Dimethyl-3,4,5,6-tetrakis(nitrooxymethyl)azepan-1-yl] 2-methylpropanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: [2,2-Dimethyl-3,4,5,6-tetrakis(nitrooxymethyl)azepan-1-yl] 2-methylpropanoate
• 英文别名: [2,2-dimethyl-3,4,5,6-tetrakis(nitrooxymethyl)azepan-1-yl] 2-methylpropanoate
• 化学式: C16H27N5O14
• 分子量: 513.4
• InChiKey: HFVMXOBFBDOCQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  250
• 氢给体数：
  0
• 氢受体数：
  15

文献信息

• Method for treating diseases associated with oxidative stress or endothelial dysfunction using substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds
  申请人：SALZMAN GROUP, INC.

  公开号：US10000455B2

  公开（公告）日：2018-06-19

  A method reduces oxidative stress or endothelial dysfunction in a mammal. The method includes administering to the mammal a compound of formula I: or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt of the compound.

  一种减少哺乳动物氧化应激或内皮功能障碍的方法。 该方法包括向哺乳动物施用式 I 的化合物：或该化合物的对映体、非对映体、外消旋体或药学上可接受的盐。
• PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF
  申请人：Radikal Therapeutics Inc.

  公开号：EP2964218A2

  公开（公告）日：2016-01-13
• METHOD FOR TREATING DISEASES ASSOCIATED WITH OXIDATIVE STRESS OR ENDOTHELIAL DYSFUNCTION
  申请人：RADIKAL THERAPEUTICS INC.

  公开号：US20170327466A1

  公开（公告）日：2017-11-16

  A method reduces oxidative stress or endothelial dysfunction in a mammal. The method includes administering to the mammal a compound of formula I: or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt of the compound.
• US9604932B2
  申请人：——

  公开号：US9604932B2

  公开（公告）日：2017-03-28
• [EN] PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF<br/>[FR] PROMÉDICAMENTS DE DÉRIVÉS D'OXYDES D'AZOTE MULTIFONCTIONNELS ET LEURS UTILISATIONS
  申请人：RADIKAL THERAPEUTICS INC

  公开号：WO2014136059A2

  公开（公告）日：2014-09-12

  The invention provides prodrugs of compounds comprising a nitric oxide donor and a reactive oxygen species (ROS) degradation catalyst, in particular, 1-pyrrolidinyloxy, 1- piperidinyloxy, and 1-azepanyloxy derivatives, and pharmaceutical compositions thereof. These compounds and pharmaceutical compositions are useful in prevention, treatment or management of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.